NO20025375L - Fremgangsmåte for behandling og midler som er nyttige for behandlingen - Google Patents

Fremgangsmåte for behandling og midler som er nyttige for behandlingen

Info

Publication number
NO20025375L
NO20025375L NO20025375A NO20025375A NO20025375L NO 20025375 L NO20025375 L NO 20025375L NO 20025375 A NO20025375 A NO 20025375A NO 20025375 A NO20025375 A NO 20025375A NO 20025375 L NO20025375 L NO 20025375L
Authority
NO
Norway
Prior art keywords
treatment
cancers
agents useful
growth
present
Prior art date
Application number
NO20025375A
Other languages
English (en)
Norwegian (no)
Other versions
NO20025375D0 (no
Inventor
Mathew Vadas
Jennifer Gamble
Pu Xia
Lijun Wang
Original Assignee
Medvet Science Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medvet Science Pty Ltd filed Critical Medvet Science Pty Ltd
Publication of NO20025375D0 publication Critical patent/NO20025375D0/no
Publication of NO20025375L publication Critical patent/NO20025375L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20025375A 2000-05-11 2002-11-08 Fremgangsmåte for behandling og midler som er nyttige for behandlingen NO20025375L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ7447A AUPQ744700A0 (en) 2000-05-11 2000-05-11 A method of treatment and agents useful for same
PCT/AU2001/000539 WO2001085953A1 (en) 2000-05-11 2001-05-11 Sphingosine kinase and uses thereof

Publications (2)

Publication Number Publication Date
NO20025375D0 NO20025375D0 (no) 2002-11-08
NO20025375L true NO20025375L (no) 2003-01-07

Family

ID=3821526

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025375A NO20025375L (no) 2000-05-11 2002-11-08 Fremgangsmåte for behandling og midler som er nyttige for behandlingen

Country Status (17)

Country Link
US (1) US20040014635A1 (de)
EP (1) EP1290182B1 (de)
JP (1) JP2003532423A (de)
CN (1) CN1436241A (de)
AT (1) ATE492276T1 (de)
AU (3) AUPQ744700A0 (de)
BR (1) BR0110759A (de)
CA (1) CA2408196A1 (de)
DE (1) DE60143697D1 (de)
HK (1) HK1054409A1 (de)
IL (1) IL152672A0 (de)
MX (1) MXPA02011112A (de)
NO (1) NO20025375L (de)
NZ (1) NZ543272A (de)
RU (1) RU2326690C2 (de)
WO (1) WO2001085953A1 (de)
ZA (1) ZA200209066B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423527B1 (en) 1997-09-29 2002-07-23 Children's Hospital Medical Center Of Northern California Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
ES2523856T3 (es) 2000-12-22 2014-12-02 Lpath, Inc. Anticuerpos de esfingosina-1-fosfato para el tratamiento de enfermedades asociadas con elevadas concentraciones de esfingolípidos
CA2473680C (en) * 2002-01-17 2010-08-10 Children's Hospital & Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
US7674580B2 (en) 2002-01-17 2010-03-09 Children's Hospital & Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
AU2003215426A1 (en) * 2002-03-28 2003-10-13 Medvet Science Pty. Ltd. A method of modulating cellular activity
MXPA05003974A (es) * 2002-10-14 2005-08-03 Medvet Science Pty Ltd Un metodo de modulacion de la actividad celular epitelial mediante la modulacion de los niveles funcionales de la esfingosina cinasa.
CA2506243A1 (en) * 2002-11-19 2004-06-03 Amgen Inc. Amplified genes involved in cancer
EP1765384A4 (de) * 2004-06-15 2009-07-08 Medvet Science Pty Ltd Verfahren zur modulierung der zellulären aktivität mit sphingosinkinase und mitteln dafür, und sphingosinkinase-varianten
CA2581061C (en) * 2004-10-28 2014-09-02 Lpath Therapeutics, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US8324237B2 (en) * 2005-05-20 2012-12-04 Smith Charles D Methods for the treatment and prevention of inflammatory diseases
US20060270631A1 (en) * 2005-05-26 2006-11-30 Smith Charles D Methods for the treatment and prevention of angiogenic diseases
WO2006135968A1 (en) * 2005-06-21 2006-12-28 Medvet Science Pty. Ltd. Modulation of sphingosine kinase signalling
JP2008546720A (ja) * 2005-06-21 2008-12-25 メドベット サイエンス ピーティーワイ． リミティッド スフィンゴシンキナーゼシグナル伝達の調節によるｅｇｆｒシグナル伝達の調節
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
ES2524059T3 (es) 2006-10-27 2014-12-03 Lpath, Inc. Composiciones y procedimientos de unión a esfingosina-1-fosfato
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
WO2019182191A1 (ko) * 2018-03-21 2019-09-26 경북대학교 산학협력단 C0x2 아세틸화제를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583160A (en) * 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
US5068175A (en) * 1989-05-26 1991-11-26 Board Of Regents, The University Of Texas Sysem Method of detecting ras oncogene related malignancies
JPH10182627A (ja) * 1996-12-20 1998-07-07 Sankyo Co Ltd 新規化合物Ｓ−１５１８３ａ及びＳ−１５１８３ｂ
US6649362B2 (en) * 1997-09-08 2003-11-18 Medvet Science Pty. Ltd. Screening method for an agent having an effect on a sphingosine kinase signaling pathway
AUPO900297A0 (en) * 1997-09-08 1997-10-02 Medvet Science Pty. Ltd. A method of modulating cellular activity
EP1235913A2 (de) * 1998-05-26 2002-09-04 Sarah Spiegel Sphingosin-kinase, klonierung, expression und verfahren zur anwendung
BR9912501A (pt) * 1998-06-29 2001-05-02 Los Angeles Childrens Hospital Tratamento de distúrbios hiperproliferativos
ATE323153T1 (de) * 1999-05-13 2006-04-15 Johnson & Johnson Pharm Res Sphingosinekinase
BR0015138A (pt) * 1999-10-28 2002-07-16 Warner Lambert Co Gene da esfingosina quinase humana
US6830916B2 (en) * 2000-03-02 2004-12-14 Sarah Spiegel Sphingosine kinase, cloning, expression and methods of use
CA2404965A1 (en) * 2000-04-03 2001-10-11 Sankyo Company, Limited Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof
MXPA05003974A (es) * 2002-10-14 2005-08-03 Medvet Science Pty Ltd Un metodo de modulacion de la actividad celular epitelial mediante la modulacion de los niveles funcionales de la esfingosina cinasa.

Also Published As

Publication number Publication date
ZA200209066B (en) 2004-04-07
US20040014635A1 (en) 2004-01-22
MXPA02011112A (es) 2004-08-19
ATE492276T1 (de) 2011-01-15
CN1436241A (zh) 2003-08-13
EP1290182A1 (de) 2003-03-12
AUPQ744700A0 (en) 2000-06-01
AU2001256001B2 (en) 2007-03-15
IL152672A0 (en) 2003-06-24
NZ543272A (en) 2009-04-30
CA2408196A1 (en) 2001-11-15
HK1054409A1 (zh) 2003-11-28
NO20025375D0 (no) 2002-11-08
WO2001085953A1 (en) 2001-11-15
EP1290182B1 (de) 2010-12-22
EP1290182A4 (de) 2006-01-11
AU5600101A (en) 2001-11-20
JP2003532423A (ja) 2003-11-05
DE60143697D1 (de) 2011-02-03
BR0110759A (pt) 2003-05-06
RU2326690C2 (ru) 2008-06-20

Similar Documents

Publication Publication Date Title
NO20025375L (no) Fremgangsmåte for behandling og midler som er nyttige for behandlingen
GB0318438D0 (en) Early entry
SG148864A1 (en) Methods of treating cancer and related methods
MY112949A (en) Benzo-thiaphene estrogen agonists to treat prostatic hyperplasia
HUP0402656A2 (hu) Sejtterápiás eljárás tumorok kezelésére
PT1294747E (pt) Métodos de síntese para aplidina e novos derivados antitumorais e seus métodos de produção e utilização
ATE438618T1 (de) Inhibitoren von humanem adam-10
DE60025905D1 (de) In vitro methode zur synchronisation von oozytenreifung
IL150060A0 (en) Novel purines
EP1532131A4 (de) Motilidverbindungen
DE60218153D1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
HUP0102967A2 (hu) Eljárás organoszilil-alkilpoliszulfánok előállítására
TR200101693T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
MY138550A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
MY139159A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
TR200200278T2 (tr) Kalsilitik bileşimler
MY139348A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
AU2002220712A1 (en) Stem cells, method for expansion in vitro and use thereof
MXPA04004526A (es) N-metil-homocisteinas, su uso y metodo para su produccion.
MY139443A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
GB9425071D0 (en) Chondrocyte cell lines
PT1406512E (pt) Tratamento de substratos lenhocelulósicos com ozono
ATE454168T1 (de) Calcium-ergänzung zur senkung des risikos für prostatakrebs
DE60114876D1 (de) DEKONTAMINATION VON PRIONHALTIGEM (z.B. BSE-AGENS ENTHALTENDEM) TIERFUTTER
UA32153A (uk) Спосіб формування трансплантату для зведення на промежину при черевно-анальних резекціях прямої кишки

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application